Fig. 2From: Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patientsLikelihood of having a reduced initial dose of Capecitabine or 5FU compared to patients without a variant (after adjusting for confounding)Back to article page